A microfluidic fluorescence lifetime screening platform bridges in vitro and in vivo formats and enables discovery of Amyloid β aggregation inhibitors
Abstract Inhibiting the aggregation of Amyloid β (1-42) is a promising strategy for the development of disease-modifying Alzheimer’s disease therapeutics. To date, however, no sufficiently efficacious inhibitors have been identified, despite the best efforts of more than 200 advanced drug development campaigns. This failure can be partially attributed to limitations in current in vitro compound screening and in vivo validation assays. Here, we report a high throughput assay platform based on the use of a fluorescence lifetime aggregation sensor that can be applied in vitro and in vivo. This microfluidic “nanoFLIM” assay presents a cost-effective and reliable alternative to conventional early-stage small molecule discovery platforms for cell-free Amyloid β aggregation. The fluorescence lifetime sensor can dynamically monitor peptide aggregation in cellular and Caenorhabditis elegans disease models, providing directly comparable aggregation kinetics, which is not achievable by any other method. The power of this unified platform for accelerating hit-to-lead strategies, lowering attrition rates and expediting in vivo screening, was demonstrated with a pilot screening campaign of 445 compounds, revealing an inhibitor that can inhibit Amyloid β self-assembly both in vitro as well as in cellular and whole organism disease models.
Authors
- Clemens F. Kaminski (ORCID: https://orcid.org/0000-0002-5194-0962)
- Gianluigi Veglia (ORCID: https://orcid.org/0000-0002-2795-6964)
- Súil Collins
- Liisa van Vliet (ORCID: https://orcid.org/0000-0002-5196-7073)
- Fabrice Gielen (ORCID: https://orcid.org/0000-0003-0604-7224)
- Giuliana Fusco (ORCID: https://orcid.org/0000-0002-3644-9809)
- Florian Hollfelder (ORCID: https://orcid.org/0000-0002-1367-6312)
- Nino F. Läubli (ORCID: https://orcid.org/0000-0003-2894-2385)
- Gabriele S. Kaminski Schierle (ORCID: https://orcid.org/0000-0002-1843-2202)
- Tomáš Deingruber (ORCID: https://orcid.org/0000-0002-6017-9490)
- David R. Spring (ORCID: https://orcid.org/0000-0001-7355-2824)
- Ana Fernández‐Villegas (ORCID: https://orcid.org/0000-0002-9766-8722)
- M. Janecek (ORCID: https://orcid.org/0000-0003-0740-641X)
- Chetan Poudel (ORCID: https://orcid.org/0000-0002-8512-9238)
- Claire Michel
- Sara Wagner Valladolid
Institutions
- University of Exeter (GB)
- University of Cambridge (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1038/s41467-026-78202-8
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- Cambridge Trust
- Directorate for Biological Sciences
- Horizon 2020 Framework Programme
- Medical Research Council
- Biotechnology and Biological Sciences Research Council